Literature DB >> 34375485

Serum neurofilament light chain as a surrogate of cognitive decline in sporadic and familial frontotemporal dementia.

Anuschka Silva-Spínola1,2, Marisa Lima1,3,4, Maria João Leitão1, João Durães1,3,5, Miguel Tábuas-Pereira1,3,5, Maria Rosário Almeida1, Isabel Santana1,3,5, Inês Baldeiras1,5.   

Abstract

BACKGROUND AND
PURPOSE: Neurofilament light chain (NfL) has recently been proposed as a promising biomarker in frontotemporal dementia (FTD). We investigated the correlation of both cerebrospinal fluid (CSF) and serum NfL with detailed neuropsychological data and cognitive decline in a cohort of sporadic and familial FTD.
METHODS: CSF and serum NfL, as well as conventional CSF Alzheimer's disease (AD) biomarkers (Aβ42, t-Tau, p-Tau181), were determined in 63 FTD patients (30 sporadic-FTD, 20 with progranulin (GRN) mutations [FTD-GRN], 13 with chromosome 9 open reading frame 72 [C9orf72] expansions [C9orf72-FTD]), 37 AD patients, and 31 neurologic controls. Serum NfL was also quantified in 37 healthy individuals. Correlations between baseline CSF and serum NfL levels, standardized neuropsychological tests, and the rate of cognitive decline in FTD patients were assessed.
RESULTS: CSF and serum NfL presented with significantly higher levels in FTD than in AD patients and both control groups. Within FTD subtypes, genetic cases, and particularly FTD-GRN, had higher CSF and serum NfL levels. Significant correlations between NfL levels and overall cognitive function, abstract reasoning (CSF and serum), executive functions, memory, and language (serum) were found. A relationship between increased baseline CSF and serum NfL and a decay in cognitive performance over time was also observed.
CONCLUSIONS: Our findings highlight the potential of serum NfL as a useful surrogate end point of disease severity in upcoming targeted treatments.
© 2021 European Academy of Neurology.

Entities:  

Keywords:  biomarkers; cognition; frontotemporal dementia; neurofilament light chain; serum

Mesh:

Substances:

Year:  2021        PMID: 34375485     DOI: 10.1111/ene.15058

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  2 in total

Review 1.  Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis.

Authors:  Patrizia LoPresti
Journal:  Biomedicines       Date:  2022-05-06

2.  Glial profiling of human tauopathy brain demonstrates enrichment of astrocytic transcripts in tau-related frontotemporal degeneration.

Authors:  Ashlyn G Johnson; James A Webster; Chadwick M Hales
Journal:  Neurobiol Aging       Date:  2021-12-24       Impact factor: 4.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.